Tracy Speight, MD
Obstetrics & Gynecology · Dallas, TXNPI 1831143148
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Celularity Inc. at 48.3% of the total. Reporting peaked in 2019 at $1,200 and has fallen 74.6% since, to $305 in 2025.
Across 63 payments — averaging $39.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$1K
- Astellas Pharma US Inc$243
- AbbVie$181
- Exeltis, USA Inc.$113
- Pfizer$109
- Gynesonics, Inc.$89
- plus $550 from 16 others
Across 3 payments — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exeltis, USA Inc.$12K
What the payments were for
- Speaking & faculty fees$1,20048%
- Food & beverage$1,21149%
- Education$733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 4 | $1,200 |
| Astellas Pharma US Inc | 10 | $243 |
| AbbVie(2 entities) | 9 | $181 |
| Exeltis, USA Inc. | 6 | $113 |
| Pfizer | 6 | $109 |
| Gynesonics, Inc. | 2 | $89 |
| Millicent US Inc | 4 | $87 |
| Mayne Pharma Commercial LLC | 3 | $73 |
| Minerva Surgical, Inc | 2 | $69 |
| Organon | 3 | $63 |
| Channel Medsystems, Inc. | 1 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Ascend Therapeutics US, LLC | 2 | $27 |
| Innovation Technologies Inc | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $21 |
| Aspira Women's Health Inc | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Amgen | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $14 |
How this compares
$2,484 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 41 | $2,204 |
| ProgesteroneProgesterone, Micronized | 18 | $806 |
| Zolpidem Tartrate | 16 | $125 |
| Alprazolam | 18 | $41 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.